What is a Tearsheet?
A tearsheet (also spelled “tear sheet”) is a concise, one-to-two-page company profile that summarizes the most important facts about a business. The name comes from the practice of literally tearing a page out of a financial reference book to share with colleagues. Today, tearsheets are generated digitally but serve the same purpose: giving a professional a quick, structured overview of a company without having to dig through full financial filings or research reports. Tearsheets are used across the financial industry: equity research analysts use them as investment snapshots, investment bankers use them in M&A contexts to profile targets and acquirers, corporate development teams use them to evaluate potential acquisitions, and sales teams use them to prepare for client meetings. The content and emphasis differ by audience, but the goal is always the same: present the essential facts in a professional, digestible format.Why It Matters
In finance, time is the most valuable resource. Before a meeting, a call, or a decision, professionals need to quickly get up to speed on a company. A well-constructed tearsheet saves hours of research by presenting the key information — financial performance, valuation, competitive positioning, and recent activity — in a standardized format. Consistency matters too: when every company is profiled in the same format, comparisons become much easier.Key Concepts
| Term | Definition |
|---|---|
| Audience Type | The intended reader determines which data is emphasized: Equity Research (valuation and earnings), IB/M&A (strategic positioning and deal angles), Corp Dev (strategic fit and integration), Sales/BD (conversation starters) |
| LTM | Last Twelve Months — trailing 12-month financial figures |
| NTM | Next Twelve Months — forward 12-month consensus estimates |
| ACV | Annual Contract Value — for SaaS/subscription companies, the annualized value of contracts |
| Pro Forma | Adjusted figures that account for pending transactions (e.g., revenue excluding a divested segment) |
Audience Types
Equity Research
Investment thesis snapshot for buy-side/sell-side analysts. Concise 1-page format with valuation comps and earnings highlights.
IB / M&A
Company profile in transaction context. 1-2 pages with M&A activity, strategic positioning, and deal angle analysis.
Corp Dev
Acquisition target profile for internal strategic teams. 1-2 pages with strategic fit analysis and integration considerations.
Sales / BD
Client meeting prep for commercial teams. 1-2 pages with conversation starters and relationship context.
How It Works
Identify Inputs
Gather: company name or ticker, audience type (Equity Research, IB/M&A, Corp Dev, Sales/BD), comparable companies (optional), page length preference.
Pull Data via S&P Global MCP
Execute the query plan for the audience type, pulling 4 fiscal years of financial data (the 4th year is needed for YoY growth calculations). Write intermediate files after each query step.
Calculate Derived Metrics
Compute margins, growth rates, efficiency ratios, capital structure metrics, and segment mix. Validate all arithmetic.
Worked Example: Equity Research Tear Sheet
Company: Meridian Healthcare (MHC)
Header Banner (Navy #1F3864 background, white text): MERIDIAN HEALTHCARE INC.| Left Column | Right Column |
|---|---|
| Ticker: NYSE: MHC | Market Cap: $12.4B |
| HQ: Nashville, TN | Enterprise Value: $14.8B |
| Founded: 2005 | Stock Price: $82.50 |
| Employees: 8,200 | Shares Out: 150.3M |
| Sector: Healthcare Services | Beta: 0.85 |
Business Overview
Meridian Healthcare is a leading provider of outpatient healthcare services across 220 locations in 18 states. The company operates physical therapy clinics, urgent care centers, and ambulatory surgery centers. Revenue is driven by patient volume and reimbursement rates across commercial (62%), Medicare (25%), and Medicaid (13%) payors.Financial Summary
| Metric | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|
| Revenue ($M) | 3,200 | 3,680 | 4,150 | +15% CAGR |
| Gross Margin | 38.2% | 39.5% | 40.1% | Expanding |
| EBITDA ($M) | 480 | 588 | 685 | +19% CAGR |
| EBITDA Margin | 15.0% | 16.0% | 16.5% | Expanding |
| Diluted EPS | $2.95 | $3.42 | $4.05 | +17% CAGR |
| FCF ($M) | 320 | 395 | 460 | FCF/NI >100% |
| Net Debt/EBITDA | 2.8x | 2.2x | 1.8x | Deleveraging |
| Revenue Growth | 12.5% | 15.0% | 12.8% | Stable low-teens |
Valuation Comparison
| Metric | MHC | Peer Median | Premium/Discount |
|---|---|---|---|
| NTM P/E | 18.5x | 16.2x | +14% premium |
| NTM EV/EBITDA | 12.8x | 11.0x | +16% premium |
| LTM P/E | 20.4x | 18.5x | +10% premium |
| PEG Ratio | 1.35x | 1.45x | -7% discount |
| Dividend Yield | 1.2% | 0.8% | Higher |
Earnings Highlights (Most Recent Quarter)
- Revenue of $1,080M (+13% y/y) driven by 8% same-store volume growth and 5% revenue per visit increase
- EBITDA margin expanded 60bp y/y to 16.8%, benefiting from operating leverage and procurement savings
- Management guided FY2026 revenue of $4,650-4,750M (+12-14%) and EBITDA margin of 17.0-17.5%
- CEO commented: “Our multi-site operating model is delivering consistent execution, and we see significant runway for de novo expansion in underserved markets”
Peer Comparison Table
| Ticker | Company | Mkt Cap | NTM P/E | NTM EV/EBITDA | Rev Growth | EBITDA Margin |
|---|---|---|---|---|---|---|
| MHC | Meridian Healthcare | $12.4B | 18.5x | 12.8x | 13% | 16.5% |
| PTS | PhysioTherapy Systems | $8.2B | 16.0x | 11.2x | 10% | 14.8% |
| UHC | UrgentCare Holdings | $6.5B | 14.5x | 9.8x | 8% | 13.2% |
| ASC | AmbulatorySurg Corp | $15.1B | 19.2x | 13.5x | 15% | 18.0% |
| OPC | OutPatient Care | $4.8B | 12.8x | 8.5x | 6% | 12.5% |
Investment Thesis (Equity Research Audience)
Bull Case: Meridian’s multi-site platform model generates consistent double-digit revenue growth with expanding margins. The company’s PEG ratio of 1.35x is below peer median despite higher growth, suggesting the premium valuation is justified. Deleveraging from 2.8x to 1.8x net debt/EBITDA in 2 years provides financial flexibility for M&A and buybacks. Bear Case: Healthcare services companies face reimbursement risk from government payors (38% of revenue). Labor costs for therapists and clinicians are rising 5-7% annually, which could compress margins if not offset by volume growth and pricing power. At 18.5x NTM P/E, the stock prices in continued double-digit growth.Audience-Specific Customization
IB/M&A Tear Sheet Additions
- M&A activity section: recent acquisitions, rumored transactions, potential acquirers
- Strategic positioning: market share, competitive moat, defensibility
- Deal angle analysis: who would buy this company and why? What is the likely transaction structure?
Corp Dev Tear Sheet Additions
- Strategic fit analysis: how does this company complement the acquirer’s existing business?
- Integration considerations: cultural fit, technology compatibility, geographic overlap
- Pro forma impact: what would the combined entity look like on revenue, margin, and valuation?
Sales/BD Tear Sheet Additions
- Conversation starters: recent news, strategic initiatives, pain points the company has publicly discussed
- Relationship context: existing vendor relationships, key decision-makers, budget cycle timing
- Plain language business description (no financial jargon)
Daily Workflow for Tear Sheet Generation
New Request (30-60 min): Receive company name and audience type. Run the full data collection pipeline via S&P Global MCP. Write intermediate files after each query. Calculate derived metrics. Generate the DOCX. QA (15 min): Review the generated tear sheet for data accuracy, formatting consistency, and audience-appropriate content. Verify that financial tables tie and that derived metrics (margins, growth rates) are calculated correctly. Distribution: Save to the output directory and present to the requesting user. Note any data gaps or limitations.Practice Exercise
Generate a tear sheet for the following company: Company: CyberShield Corp (CSHL), a cybersecurity company providing endpoint detection and response (EDR) to enterprise clients Audience: IB / M&A (the investment bank is evaluating CSHL as a potential acquisition target for a large tech company) Financial Data:- Revenue: $800M (FY2025), growing 28% y/y
- ARR: $850M
- Gross Margin: 72%
- EBITDA Margin: 18% (improving from 12% two years ago)
- NDR: 128%
- Customers: 4,200 enterprise accounts
- Top customer: 3.5% of ARR
- Market Cap: $18B
- Enterprise Value: $17.5B (net cash position)
- Build the header banner with the appropriate key-value pairs for an IB/M&A audience.
- Write the business overview section (2-3 sentences, IB-appropriate tone — pitchbook prose, not earnings call summary).
- Build the financial summary table (4 fiscal years, with the oldest year used for YoY growth calculation).
- Create a valuation comparison table with 4-5 cybersecurity peers.
- Write the M&A-specific sections: strategic positioning (who would buy this and why?), potential acquirers (name 3 with rationale), and likely deal parameters (EV range, premium, structure).
- Draft 3 synthesis bullets for the “Deal Angle” section that connect data points into analytical narrative.
Common Mistakes
- Pasting CIQ company summaries verbatim. The CIQ company summary is an input, not an output. Rewrite every narrative section for the specific audience. An equity research overview emphasizes investment merit; an IB overview emphasizes strategic positioning; a sales overview uses plain language.
- Not pulling 4 fiscal years of data. You need 4 years to compute YoY growth for the oldest displayed year. Without the 4th year, the earliest year shows “N/A” for growth — which looks like missing data.
- Using training knowledge to fill data gaps. If the S&P Global tools do not return a number, label it “N/A” or “Not disclosed.” Do not estimate from memory — financial data becomes stale quickly and stale data in a professional document is worse than no data.
- Inconsistent number formatting. Negatives should be in parentheses: (2.3%), not -2.3%. Currency should use millions unless revenue exceeds $50B (then billions with one decimal). Table cells show plain numbers with commas — dollar signs go in column headers only.
- Missing the footer. Every tear sheet must include: “Data: S&P Capital IQ via Kensho | Analysis: AI-generated | [Date]” and “For informational purposes only. Not investment advice.” This is required on every page.
- Using the same bullets across audience types. The same earnings call produces different takeaways for different readers. Equity research wants consensus beat/miss. IB wants margin trajectory and M&A commentary. Sales wants strategic themes for conversation starters. Customize the synthesis for each audience.
- Not including NTM multiples when available. Forward multiples are the primary valuation reference for equity research and IB audiences. If the tools return both LTM and NTM, both must appear. Never show only trailing multiples when forward data exists.
- Showing segment percentages that do not sum to 100%. When computing segment mix, use consolidated revenue as the denominator, not the sum of segments (which may include intersegment eliminations). Verify that percentages add to approximately 100%.
-
Black background tables. Always use
ShadingType.CLEARin docx-js. UsingShadingType.SOLIDcauses black table backgrounds — a common formatting bug that makes the document unusable. - Not flagging pending divestitures. If a company has announced a divestiture, note it in the segment table and include pro-forma revenue excluding the divested segment. Readers need to evaluate the “go-forward” business.
How to Add to Your Local Context
Best Practices
- Always include forward (NTM) multiples when available — they are more relevant than trailing multiples for valuation
- Rewrite every narrative for the audience — never paste CIQ company summaries verbatim
- Synthesis sections are the differentiator — connect data points into analytical narrative
- Negatives should be in parentheses: (2.3%), not -2.3%
- Never downgrade known transaction values to “Undisclosed”
- Use consolidated revenue as the denominator for segment percentages
- Pull 4 fiscal years of data to enable YoY growth calculations for all displayed years
- Label all data gaps as “N/A” or “Not disclosed” — never fill gaps with training knowledge
- The footer with data source, AI disclaimer, and date must appear on every page
- Validate all arithmetic: margins = component / revenue, growth rates = (current - prior) / prior, segment percentages sum to ~100%